Corporate Profile
We are a clinical-stage biopharmaceutical company committed to overcome tumor-resistant cancer.
Our pipeline consists of small-molecule product candidates that target ALDH1 enzyme, and we intend to pair them with molecular or cellular diagnostics to identify those patients most likely to respond to treatment.
Advanced BioDesign is presently seeking additional funding, amounting to €25 million (Series A), to initiate the pivotal Phase II clinical trial in AML and prepare for expansion into solid tumors. This step paves the way for potential partnerships with pharmaceutical companies and a significant exit strategy within the next two years.
Investors
Xerys Funds
Xerys Invest is a portfolio management company specializing in private equity, offering opportunities to invest in a portfolio of holdings focused on addressing compelling issues and large-scale challenges, such as healthcare and the environment. Xerys Invest aims to provide investors with the opportunity to support carefully selected companies at various stages of their development. Depending on their expectations and profiles, investors can choose to invest in each of our holdings through a variety of investment vehicles.
Contributors
BPI France
Bpifrance finances companies at every stage of their development through loans, guarantees, and equity investments. Through various funding channels (APT, AR, PTZ), Advanced BioDesign has benefited from Bpifrance’s support and continues to do so today through calls for projects such as iNov, iDEMO, France Relance, and France 2030, for which the company has been a laureate.
Advanced BioDesign 